The last day for trading in the warrants of series TO 5 in Idogen AB is today, September 27, 2022

Today, September 27, 2022, is the last day for trading in warrants of series TO 5 (“Warrants”) in Idogen AB (“Idogen” or the “Company”). The subscription period for the Warrants runs until September 29, 2022. Three (3) Warrants gives the right to subscribe for one (1) new share in Idogen at a subscription price of SEK 0.77 per share.

If all Warrants are exercised for subscription of shares, Idogen will receive approximately MSEK 25.4 before issue costs. In order for the Warrants not to lapse without value, the holder must actively subscribe for shares no later than September 29, 2022, or alternatively sell Warrants no later than today, September 27, 2022. Please note that some trustees may close their registration earlier than September 29, 2022.

Terms for the Warrants:

• Subscription period: September 15 – 29, 2022
• Issue volume: 98,873,460 Warrants, corresponding to 32,957,820 shares upon full exercise. If the Warrants are fully exercised, the Company will receive approximately MSEK 25.4 before issue costs
• Subscription price: SEK 0.77 SEK per share
• Last day for trading in Warrants: September 27, 2022
• Planned date for press release on outcome: October 3, 2022
• Planned date for conversion to shares: October 10-14, 2022

Note that Warrants that have not been actively sold by September 27, 2022, at the latest or alternatively have exercised for subscription of shares by September 29, 2022, will expire and lose their value.

Exercise of Warrants

Trustee-registered Warrants

If the warrant holder holds Warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the Warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercising of the Warrants.

Directly registered Warrants (securities account)

Registration is done through a registration form available on the websites of Vator Securities and Idogen. Payment is made in accordance with the instructions on the registration form. Both the registration form and payment must be submitted to Vator Securities by 5:00 p.m. CEST on September 29, 2022, at the latest.

For more information on the Warrants, please visit Idogen's website (http://www.idogen.com/).

Lund, September 27, 2022

Idogen AB (publ)

For further information, please contact:

Christina Herder, acting CEO, Idogen AB

Phone: +46 (0)70374 71 56

Email: christina.herder@idogen.com

The information was submitted for publication, through the agency of the contact person set out above, on September 27, 2022 at 08.03 a.m. CEST.

Certified Adviser

Vator Securities AB

Idogen's (Nasdaq First North Growth Market: IDOGEN) unique technology platform enables the development of various tolerogenic cell therapies with the potential to restore the immune system's tolerance to counteract its attacks against, for example, biological drugs, transplanted organs or the body's own tissue. The company's most advanced program IDO 8 aims to treat hemophilia patients who have developed an unwanted immune response to their drug treatment. As previously announced, Idogen has received approval from the Swedish and Norwegian pharmaceutical authorities to conduct the first clinical phase I/IIa study with its drug candidate within the IDO 8 program in patients with severe bleeding disorders, so-called hemophilia. The company's second development program, IDO T, aims to prevent rejection of transplanted kidneys. In an additional program, IDO AID, Idogen focuses on developing treatment for various autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-term effect. The fact that a short treatment intervention has the potential to produce a very long-lasting effect is a major health economic benefit for both patients and care units. More information about Idogen is available via https://www.idogen.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Idogen. An offer to concerned persons to subscribe for units consisting of shares and warrants series TO 5 in Idogen has only been made through the prospectus that Idogen published on January 20, 2022.